Mesa Laboratories (MLAB) CFO John Sakys Sells 2,717 Shares

On June 15, 2026, John Sakys, the Chief Financial Officer of MLAB, sold 2,717 shares of the company. The transaction occurred at a trading price of $104.08 per share. Sakys's sale was not part of a pre-arranged trading plan.

Insider Buying and Selling at Mesa Laboratories, Inc.

John Sakys, MLAB's CFO, conducted multiple transactions on June 15, 2026. Besides selling 2,717 shares, he also sold 3,951 shares in another transaction. Meanwhile, Brian David Archbold, Senior Vice President of Operations, sold 1,780 shares and 2,454 shares in separate transactions on the same day.

Other Institutional Activity in MLAB

Several institutional investors have been active in MLAB recently. Long Path Partners LP significantly increased its holdings, adding 178,360 shares to reach a total of 405,583 shares valued at approximately $35.9 million. BlackRock, Inc. slightly reduced its position by 4,815 shares, ending with 393,851 shares worth about $34.8 million. Boston Partners, however, increased its stake by 55,335 shares, bringing its total to 268,711 shares valued at roughly $23.8 million.

Mesa Laboratories, Inc. Stock Down 17.7%

Shares of MLAB are trading around $104.08. The stock's performance includes a 52-week range, a 50-day moving average, and a 200-day moving average, though specific values were not detailed. Investors keep a close watch on these metrics to gauge the stock's volatility and potential future movements.

Analysts Set New Price Targets

Wells Fargo maintained its 'hold' rating for MLAB on February 4, 2026, with a price target of $94. This follows a series of ratings adjustments by Wells Fargo over the past year, reflecting varied assessments of the stock's potential. Evercore ISI has consistently maintained a 'buy' rating, with its most recent target set at $106.

About MLAB

MLAB operates in the [sector/industry] and is known for [brief description of what it does]. The company is headquartered in [location] and managed by CEO [name]. With [number of employees] employees, MLAB continues to [further description of operations or goals].

Bottom Line

The recent insider transactions at MLAB, including those by CFO John Sakys, highlight ongoing activity within the company. Investors often track such moves to gain insights into potential future performance. However, it's essential to remember that these transactions reflect past activity and may not indicate current or future strategies.